INM Insider Trading (InMed Pharmaceuticals)
Insider Ownership Percentage: 4.90%
Insider Buying (Last 12 Months): $69,849.69
Insider Selling (Last 12 Months): $0.00
InMed Pharmaceuticals Share Price & Price History
Current Price: $0.47
Price Change: ▼ Price Decrease of -0.02 (-4.08%)
As of 06/30/2022 12:43 PM ET
27 U.S. Cities Where Stocks Yield 26% a Year
From Investing Daily | Ad
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!
When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.
InMed Pharmaceuticals Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/13/2022 | Eric A. Adams | CEO | Buy | 8,560 | $0.85 | $7,276.00 | 44,843 |  |
| 1/24/2022 | Bruce S. Colwill | CFO | Buy | 5,000 | $1.09 | $5,450.00 | | |
| 1/6/2022 | Shane Aaron Johnson | SVP | Buy | 8,500 | $1.26 | $10,710.00 | | |
| 12/30/2021 | Shane Aaron Johnson | SVP | Buy | 8,093 | $1.33 | $10,763.69 | | |
| 11/15/2021 | Shane Aaron Johnson | SVP | Buy | 5,000 | $1.37 | $6,850.00 | | |
| 9/28/2021 | Bruce S. Colwill | CFO | Buy | 5,000 | $1.77 | $8,850.00 | | |
| 9/28/2021 | Eric A. Adams | CEO | Buy | 11,400 | $1.75 | $19,950.00 | | |
New Investing App Saves Investors an Average of $97,347
From Tradesmith | Ad
Most people are terrible at buying and selling stocks at the right time, but the TradeSmith app takes the emotion out of investing.
Our back test shows, the average investor would've made $97,347 more just by using the TradeSmith app analyzer software.
Check out this FREE video.
>>>
InMed Pharmaceuticals Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/17/2022 | Empery Asset Management LP | 61,741 | $58K | 0.3% | N/A | 0.437% |  |
| 8/17/2021 | Armistice Capital LLC | 890,000 | $2.83M | 0.1% | +278.7% | 9.954% | |
| 8/12/2021 | Penserra Capital Management LLC | 19,912 | $49K | 0.0% | N/A | 0.223% | |
| 5/21/2021 | Citadel Advisors LLC | 17,211 | $57K | 0.0% | N/A | 0.214% | |
| 5/18/2021 | Citadel Advisors LLC | 17,211 | $57K | 0.0% | N/A | 0.214% | |
| 5/17/2021 | Armistice Capital LLC | 235,000 | $0.78M | 0.0% | N/A | 2.919% | |
| 1/29/2021 | Creative Planning | 10,990 | $36K | 0.0% | N/A | 0.157% | |
Data available starting January 2016
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Read More on InMed Pharmaceuticals
Volume
400 shs
Average Volume
152,610 shs
Market Capitalization
$6.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of InMed Pharmaceuticals?
